<DOC>
	<DOCNO>NCT01672853</DOCNO>
	<brief_summary>The purpose study evaluate whether Simtuzumab ( GS-6624 ) effective prevent progression liver fibrosis subject PSC .</brief_summary>
	<brief_title>Simtuzumab ( GS-6624 ) Prevention Progression Liver Fibrosis Subjects With Primary Sclerosing Cholangitis ( PSC )</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult subject ( aged 1870 ) chronic cholestatic liver disease least 6 month . Liver biopsy consistent PSC : If liver biopsy perform within 3 month screen visit , tissue biopsy may use screen biopsy . Slides would recut exist tissue block submit central reader assessment . Some subject PSC may normal liver biopsy , event normal liver biopsy , subject must abnormal magnetic resonance cholangiopancreatography ( MRCP ) . MRCP consistent PSC : Some subject PSC may normal MRCP ; event normal MRCP , subject must abnormal liver biopsy . Exclusion cause liver disease include viral hepatitis , alcoholic liver disease , primary biliary cirrhosis secondary sclerosing cholangitis Must aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 10 x Central Laboratory Upper Limit Normal ( clULN ) Must serum creatinine &lt; 2.0 mg/dL A negative serum pregnancy test require female subject childbearing potential All sexually active female subject childbearing potential must agree use protocol recommend method contraception heterosexual intercourse throughout study 90 day follow last dose study medication Lactating female must agree discontinue nurse start study treatment Male subject , vasectomize , require use barrier contraception ( condom plus spermicide ) intercourse screen study completion 90 day follow last dose study drug Pregnant breast feed Evidence hepatic decompensation present , include ascites , episode hepatic encephalopathy , variceal bleed prolonged prothrombin time/international normalize ratio ( PT/INR ) Positive hepatitis C virus ( HCV ) RNA Positive HBsAg Positive antimitochondrial antibody Alcohol consumption great 21oz/week male 14oz/week female Moderately active ulcerative colitis ( UC ) define either partial Mayo score &gt; 4 , bleed score &gt; 1 , current use oral corticosteroid therapy and/or inhibitor Tumor necrosis factorα ( TNFα ) α4β7 integrin antagonist Positive urine screen amphetamine , cocaine opiate ( i.e . heroin , morphine ) screening . Subjects stable methadone buprenorphine maintenance treatment least 6 month prior screen may include study . Subjects positive urine drug screen due prescription opioidbased medication eligible prescription diagnosis review approved investigator Clinically significant cardiac disease History cholangiocarcinoma History cancer , nonmelanomatous skin cancer , within 5 year prior screen Ascending cholangitis within 60 day screen Presence percutaneous drain bile duct stent Known hypersensitivity investigation product formulation excipients History bleed diathesis within 6 month screen Unavailable followup assessment concern subject 's compliance protocol procedure ; Participation investigational trial drug device within 30 day prior screen Major surgical procedure within 30 day prior screen presence open wound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PSC</keyword>
	<keyword>Sclerosis</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>LOXL2</keyword>
	<keyword>Simtuzumab</keyword>
	<keyword>Primary sclerosing cholangitis</keyword>
	<keyword>Liver fibrosis</keyword>
	<keyword>Liver disease</keyword>
	<keyword>MRCP</keyword>
	<keyword>MRE</keyword>
	<keyword>Liver biopsy</keyword>
</DOC>